Rafif Dali, Zeina Hamama, Nader Abdullah
email@example.com , firstname.lastname@example.org
Rafif Dali1*, Zeina Hamama2, Nader Abdullah3
1,2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
3Professor, Department of Oncology, Faculty of Medicine, Tishreen University, Lattakia, Syria.
Volume - 15,
Issue - 8,
Year - 2022
Early detection and treatment of breast cancer with appropriate medications and chemotherapy can lead to a cure and reduction of recurrence over time. Chemotherapy causes serious side effects, especially cardiovascular toxicities which can develop and cause more serious harm to patients, although they can be detected during the early stages of treatment by analyzing cardiac enzymes periodically during treatment. So, our study aims to follow patients to detect the incidence of side effects, especially early cardiovascular effects that can develop over time and affect the patient's life. The study included 50 breast cancer newly diagnosed patients [50 women] treated with an alkylating agent (cyclophosphamide) and an anthracin derivative (doxorubicin), the patients were treated at the Chemotherapy and Radiotherapy Center at Tishreen University Hospital. All patients were followed for three months, creatine kinase and troponin analysis were performed for each patient before starting chemotherapy and after three months of treatment. When examining the results, an increase in troponin levels was observed in three patients to 0.03 ng/ml and in six patients more than 0.03 ng/ml and there was statistically significant difference [p value < 0.05], a decrease in the value of creatine kinase was observed after three month and this decrease difference was statistically significant [p value < 0.05]. Analyzing cardiac enzymes is one of the important steps for predicting patients at greatest risk of developing cardiac toxicity, in addition to giving appropriate preventive treatment to avoid its development.
Cite this article:
Rafif Dali, Zeina Hamama, Nader Abdullah. Study of Short-term toxicity of Cyclophosphamide and Doxorubicin on the Cardiovascular System in women with Breast cancer treated at the center of radiation and chemotherapy at Tishreen University Hospital. Research Journal of Pharmacy and Technology. 2022; 15(8):3429-3. doi: 10.52711/0974-360X.2022.00574
Rafif Dali, Zeina Hamama, Nader Abdullah. Study of Short-term toxicity of Cyclophosphamide and Doxorubicin on the Cardiovascular System in women with Breast cancer treated at the center of radiation and chemotherapy at Tishreen University Hospital. Research Journal of Pharmacy and Technology. 2022; 15(8):3429-3. doi: 10.52711/0974-360X.2022.00574 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-8-16
1. Pushpa P. Mahesh A. Mokshada C. Advanced Molecular Targeted Therapy in Breast Cancer. Research Journal of Pharmacology and Pharmacodynamics 2018; 10(1):29-37.doi.org/10.5958/2321-5836.2018.00006.X
2. Breast Cancer. 2021; Available from: https://www.who.int/ar/news-room/fact-sheets/detail/breast-cancer
3. Ibrahim h. 2019 https://www.anapress.net/ar/articles
4. Jayashree V. Velraj M. Breast Cancer and Various Prognostic Biomarkers for the Diagnosis of the Disease: A Review. Research Journal of Pharmacy and Technology 2017; 10(9):3211-16.doi.org/10.5958/0974-360X.2017.00570.4
5. Suresh R. Benitojohnson D. Maheswari C. Venkatnarayanan R. Manavalan R. Chemo Preventive Activity of Triumfetta Rhomboidea in 7, 12-Dimethylbenz (a) Anthracene Induced Breast Cancer in Sprague-Dawley Rat Model. Research Journal of Pharmacy and Technology 2017; 10(3):692-87.doi.org/10.5958/0974-360X.2017.00128.7
6. Kadhem S. Ali A. Al-rikabi A. Compartment between Breast Cancer Patient Undergoing Chemotherapy and Healthy Women by Cytokinesis-Block Micronucleus Test and Nuclear Division Index. Research Journal of Pharmacy and Technology 2018; 11(2):10-705.doi.org/10.5958/0974-360X.2018.00133.6
7. Wild CP. Weiderpass E. Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. 2020:IARC Press.
8. Wang J. Lei K. Han F. Tumor Microenvironment: Recent Advances in Various Cancer Treatments. Eur Rev Med Pharmacol Sci 2018; 22: 3855-3864.doi.org/10.26355/eurrev_201806_15270
9. Tan W. Wu X. Wei S. Chemoradiotherapy-Associated Cardiovascular Toxicity: A Need of Cardio-Oncology to Improve. Journal of Clinical & Experimental Cardiology 2014; 5:320.doi.org/10.4172/2155-9880.1000320
10. Jishala M. Venkateswaramurthy N. Sambathkumar R. Cardiotoxicity Associated with Cancer Chemotherapy. Research Journal of Pharmacy and Technology 2020; 13(5):2480-87.doi.org/10.5958/0974-360X.2020.00443.6
11. Nemes A. Piros G. Domsik P. Kalapos A. Forster T. Left Atrial Volumetric and Strain Analysis by Three-Dimensional Speckle-Tracking Echocardiography in Noncompaction Cardiomyopathy: Results from the Magyar-Path Study. Hellenic Journal of Cardiology 2016; 57(1):23-29.doi.org/10.1016/S1109-9666(16)30014-8
12. Shaty M. Al-Ezzi M. Arif I. Basil D. Effect of Metformin on Inflammatory Markers Involved in Cardiotoxicity Induced by Doxorubicin. Research Journal of Pharmacy and Technology 2019; 12(12):5815-21.doi.org/10.5958/0974-360X.2019.01007.2
13. Jain D. Ahmad T. Cairo M. Aronow W. Cardiotoxicity of Cancer Chemotherapy: Identification, Prevention and Treatment. Annals of Translational Medicine 2017; 5(17):348.doi.org/10.21037/atm.2017.06.35
14. Aruna P. Gayathiri N. Cardioprotective Activity of Telmisartan, Metformin and Its Combination against Doxorubicin Induced Myocardial Infarction in Rat Model. Research Journal of Pharmacy and Technology 2018; 11(12):5293-96.doi.org/ 10.5958/0974-360X.2018.00964.2
15. Zagar T. Cardinale D. Marks L. Breast Cancer Therapy-Associated Cardiovascular Disease. Nature reviews Clinical Oncology 2016; 13(3):172-84.doi.org/10.1038/nrclinonc.2015.171.
16. Aydin S. Ugur K. Aydin S. Sahin İ. Yardim M. Biomarkers in Acute Myocardial Infarction: Current Perspectives. Vascular Health and Risk Management 2019; 15:1-10.doi.org/10.2147/VHRM.S166157
17. Horacek J. Vasatova M. Pudil R. Tichy M. Zak P. Jakla M. Jebavy L et al Biomarkers for the Early Detection of Anthracycline-Induced Cardiotoxicity: Current Status. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc 2014; 158(4):511-517.doi.org/10.5507/bp.2014.004
18. Mutaz A. Khdhair K. Salih S. The Relationship between Serum Level of Ferritin and Cardiac Troponin T (Ctnt) in Children with Major Beta-Thalassemia. Research Journal of Pharmacy and Technology 2019; 12(4):1713-16.doi.org/10.5958/0974-360X.2019.00285.3
19. Ashvarya M. Saurabh G. Eric S. Troponins 2019 https://emedicine.medscape.com/article/2073935-overview
20. Hafeez N. Creatine Phosphokinase Levels in Oral Cancer Patients. Research Journal of Pharmacy and Technology 2016; 9(10):1577-1580.doi.org/10.5958/0974-360X.2016.00310.3
21. Sudhakar S. Paul J. Selvam S. Mahendranath P. Serum Creatine Kinase Response on Exercise Induced Delayed Onset Muscle Soreness: A Pilot Single Blind Randomized Clinical Trial. Research Journal of Pharmacy and Technology 2020; 13(8):3638-3642.doi.org/10.5958/0974-360X.2020.00643.5
22. Parichart J. Saranya B. Bhaskar P. Vincent F. Eric S. Creatine Kinase 2019 https://emedicine.medscape.com/article/2074023-overview
23. Fraser A. Chemotherapy as a Cause of Low Serum Creatine Kinase Activity. Clinical Chemistry, 1980; 26(11):1629-30 /
24. Cersosimo R. Lee J. Creatine Kinase Elevation Associated with 5‐Fluorouracil and Levamisole Therapy for Carcinoma of the Colon: A Case Report. Cancer. Interdisciplinary International Journal of the American Cancer Society 1996; 77:1250-3 /
25. Jones M. O’Gorman P. Kelly C. Mahon N. Fitzgibbon M. High-Sensitive Cardiac Troponin-I Facilitates Timely Detection of Subclinical Anthracycline-Mediated Cardiac Injury. Annals of Clinical Biochemistry 2017; 54(1):149-57.doi.org/10.1177/0004563216650464
26. Tzolos E. Adamson P. Hall P. Macpherson I. Oikonomidou O. MacLean M. Lewis S et al Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Clinical Oncology 2020; 32(5):292-97.doi.org/10.1016/j.clon.2019.11.008
27. Kitayama H. Kondo T. Sugiyama J. Kurimoto K. Nishino Y. Kawada M. Hirayama M et al High-Sensitive Troponin T Assay Can Predict Anthracycline-and Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients. Breast Cancer 2017; 24(6):774-82.doi.org/10.1007/s12282-017-0778-8